Please use this identifier to cite or link to this item: http://hdl.handle.net/10201/60824

Title: Synergism of imatinib mesylate and everolimus in attenuation of bronchiolitis obliterans after rat LTX
Issue Date: 2013
Publisher: F. Hernández y Juan F. Madrid. Universidad de Murcia. Departamento de Biología Celular e Histología
Citation: Histology and Histopathology, vol. 28, nº 10 (2013)
ISSN: 1699-5848
0213-3911
Related subjects: CDU::5 - Ciencias puras y naturales::57 - Biología::576 - Biología celular y subcelular. Citología
Keywords: Lung transplantation
Rat
Abstract: Bronchiolitis obliterans (BO) is a progressive and fatal disease after lung transplantation (LTX). Dysregulated growth factor-induced proliferation of myofibroblasts seems to be responsible for the development of BO. The aim was to confirm the efficacy of both inhibitors of receptor tyrosine kinases (RTKI) and of mammalian target of rapamycin (mTORI) after rat LTX. We used a rat model of left lung allotransplantation (F344-to-WKY) to evaluate the effect of imatinib (RTKI; 20 mg/kg/day; postoperative day (POD) 0-100) alone or in combination with everolimus (mTORI; 2.5 mg/kg/day; POD 14-100). Non-treated animals were the reference. In non-treated rats, acute rejection (AR) peaked between POD 20 and 30 (19/19) and ended in chronic rejection (CR) on POD 60/100 (12/12). Imatinib alone did not prevent AR (6/6), but attenuated the degree of degenerated bronchioles on POD 30 (non-treated, 57%; imatinib, 4%), and increased the allografts free of CR on POD 60/100 (3/12). A combination of imatinib and everolimus significantly reduced AR, attenuated fibrotic degenerated bronchioles (5%) and vessels (non-treated, 24%; combination therapy, 11%) on POD 30, and reduced fibrotic degenerated vessels (non-treated, 97%; combination therapy, 43%) and bronchioles (non-treated, 88%; combination therapy, 34%) on POD 60/100. Fifty percent of the animals were completely free of BO and vasculopathy. In conclusion, co-application of RTKI and mTORI attenuated the development of BO and vasculopathy. Thus, imatinib might be an interesting therapeutic approach after LTX.
Primary author: Suesskind-Schwendi, M. von
Valenti, Verena
Haneya, Assad
Pühler, T.
Bewig, B.
Schmid, C.
Hirt, S.W.
Lehle, K.
URI: http://hdl.handle.net/10201/60824
Document type: info:eu-repo/semantics/article
Number of pages / Extensions: 12
Rights: info:eu-repo/semantics/openAccess
Appears in Collections:Vol.28, nº10 (2013)

Files in This Item:
File Description SizeFormat 
Suesskind-Schwendi-28-1273-1284-2013.pdf34,37 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons